{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:44:19Z","timestamp":1750949059157},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"DOI":"10.7759\/cureus.32998","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T14:44:46Z","timestamp":1672152286000},"source":"Crossref","is-referenced-by-count":1,"title":["The Development of Psychiatric Illness and Chemoprophylaxis of Botulinum Toxin in Migraine: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Ayushi S","family":"Dhengare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshna G","family":"Fulmali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-006-0275-5","article-title":"The history of the migraine trust","volume":"7","author":"Rose FC","year":"2006","unstructured":"Rose FC. The history of the migraine trust. J Headache Pain. 2006, 7:109-15. 10.1007\/s10194-006-0275-5","journal-title":"J Headache Pain"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15440-8","article-title":"Migraine","volume":"363","author":"Silberstein SD","year":"2004","unstructured":"Silberstein SD. Migraine. Lancet. 2004, 363:381-91. 10.1016\/S0140-6736(04)15440-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-009-0071-5","article-title":"Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications","volume":"30","author":"Baskin SM","year":"2009","unstructured":"Baskin SM, Smitherman TA. Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications. Neurol Sci. 2009, 30:S61-5. 10.1007\/s10072-009-0071-5","journal-title":"Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0988-x","article-title":"Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications","volume":"20","author":"Dresler T","year":"2019","unstructured":"Dresler T, Caratozzolo S, Guldolf K, et al.. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain. 2019, 20:51. 10.1186\/s10194-019-0988-x","journal-title":"J Headache Pain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton RB","year":"2015","unstructured":"Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015, 55:103-22. 10.1111\/head.12505_2","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.07.007","article-title":"What is the link between migraine and psychiatric disorders? From epidemiology to therapeutics","volume":"177","author":"Radat F","year":"2021","unstructured":"Radat F. What is the link between migraine and psychiatric disorders? From epidemiology to therapeutics. Rev Neurol. 2021, 177:821-6. 10.1016\/j.neurol.2021.07.007","journal-title":"Rev Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26419","article-title":"The development and impact of anxiety with migraines: a narrative review","volume":"14","author":"Kumar R","year":"2022","unstructured":"Kumar R, Asif S, Bali A, Dang AK, Gonzalez DA. The development and impact of anxiety with migraines: a narrative review. Cureus. 2022, 14:e26419. 10.7759\/cureus.26419","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0742-1","article-title":"Anxiety and depression symptoms and migraine: a symptom-based approach research","volume":"18","author":"Peres MF","year":"2017","unstructured":"Peres MF, Mercante JP, Tobo PR, Kamei H, Bigal ME. Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain. 2017, 18:37. 10.1186\/s10194-017-0742-1","journal-title":"J Headache Pain"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00559.x","article-title":"Mood and anxiety disorders in chronic headache","volume":"46","author":"Baskin SM","year":"2006","unstructured":"Baskin SM, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache. 2006, 46:S76-87. 10.1111\/j.1526-4610.2006.00559.x","journal-title":"Headache"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s101940300004","article-title":"Comorbidities of migraine: a user-friendly overview","volume":"4","author":"Carolei A","year":"2003","unstructured":"Carolei A, Ciancarelli I, Cerone D, Sacco S. Comorbidities of migraine: a user-friendly overview. J Headache Pain. 2003, 4:s23-5. 10.1007\/s101940300004","journal-title":"J Headache Pain"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00103.x","article-title":"The prevalence of migraine headaches in an anxiety disorders clinic sample","volume":"16","author":"Senaratne R","year":"2010","unstructured":"Senaratne R, Van Ameringen M, Mancini C, Patterson B, Bennett M. The prevalence of migraine headaches in an anxiety disorders clinic sample. CNS Neurosci Ther. 2010, 16:76-82. 10.1111\/j.1755-5949.2009.00103.x","journal-title":"CNS Neurosci Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0997-9","article-title":"Clinical neurophysiology of migraine with aura","volume":"20","author":"Coppola G","year":"2019","unstructured":"Coppola G, Di Lorenzo C, Parisi V, Lisicki M, Serrao M, Pierelli F. Clinical neurophysiology of migraine with aura. J Headache Pain. 2019, 20:42. 10.1186\/s10194-019-0997-9","journal-title":"J Headache Pain"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-018-0735-z","article-title":"Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks","volume":"22","author":"Vgontzas A","year":"2018","unstructured":"Vgontzas A, Burch R. Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks. Curr Pain Headache Rep. 2018, 22:78. 10.1007\/s11916-018-0735-z","journal-title":"Curr Pain Headache Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.950","article-title":"What is the actual prevalence of migraine?","volume":"8","author":"Yeh WZ","year":"2018","unstructured":"Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine?. Brain Behav. 2018, 8:e00950. 10.1002\/brb3.950","journal-title":"Brain Behav"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10090615","article-title":"Autism and migraine: an unexplored association?","volume":"10","author":"Vetri L","year":"2020","unstructured":"Vetri L. Autism and migraine: an unexplored association?. Brain Sci. 2020, 10:615. 10.3390\/brainsci10090615","journal-title":"Brain Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s8467","article-title":"Psychiatric comorbidity and suicide risk in patients with chronic migraine","volume":"6","author":"Pompili M","year":"2010","unstructured":"Pompili M, Serafini G, Di Cosimo D, et al.. Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat. 2010, 6:81-91. 10.2147\/ndt.s8467","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8551","article-title":"Is there an association between migraine and major depressive disorder? a narrative review","volume":"12","author":"Jahangir S","year":"2020","unstructured":"Jahangir S, Adjepong D, Al-Shami HA, Malik BH. Is there an association between migraine and major depressive disorder? a narrative review. Cureus. 2020, 12:e8551. 10.7759\/cureus.8551","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/389851","article-title":"Bipolar affective disorder and migraine","volume":"2012","author":"Engmann B","year":"2012","unstructured":"Engmann B. Bipolar affective disorder and migraine. Case Rep Med. 2012, 2012:1-3. 10.1155\/2012\/389851","journal-title":"Case Rep Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-010-0282-4","article-title":"Migraine and psychiatric comorbidity: a review of clinical findings","volume":"12","author":"Antonaci F","year":"2011","unstructured":"Antonaci F, Nappi G, Galli F, Manzoni GC, Calabresi P, Costa A. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain. 2011, 12:115-25. 10.1007\/s10194-010-0282-4","journal-title":"J Headache Pain"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.10.056","article-title":"Bidirectional association between migraine and depression among probands and unaffected siblings: a nationwide population-based study","volume":"279","author":"Chen M-H","year":"2021","unstructured":"Chen M-H, Pan T-L, Lin W-C, et al.. Bidirectional association between migraine and depression among probands and unaffected siblings: a nationwide population-based study. J Affect Disord. 2021, 279:687-91. 10.1016\/j.jad.2020.10.056","journal-title":"J Affect Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/jnrp.jnrp_146_18","article-title":"Migraine and mood disorders: prevalence, clinical correlations and disability","volume":"10","author":"Rammohan K","year":"2019","unstructured":"Rammohan K, Mundayadan SM, Das S, Shaji CV. Migraine and mood disorders: prevalence, clinical correlations and disability. J Neurosci Rural Pract. 2019, 10:28-33. 10.4103\/jnrp.jnrp_146_18","journal-title":"J Neurosci Rural Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.008","article-title":"The cycle of migraine: patients' quality of life during and between migraine attacks","volume":"29","author":"Freitag FG","year":"2007","unstructured":"Freitag FG. The cycle of migraine: patients' quality of life during and between migraine attacks. Clin Ther. 2007, 29:939-49. 10.1016\/j.clinthera.2007.05.008","journal-title":"Clin Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046283","article-title":"Bidirectional association between migraine and rheumatoid arthritis: two longitudinal follow-up studies with a national sample cohort","volume":"11","author":"Kim YH","year":"2021","unstructured":"Kim YH, Lee JW, Kim Y, Bae JS, Kim YJ, Min C, Choi HG. Bidirectional association between migraine and rheumatoid arthritis: two longitudinal follow-up studies with a national sample cohort. BMJ Open. 2021, 11:e046283. 10.1136\/bmjopen-2020-046283","journal-title":"BMJ Open"},{"key":"ref24","unstructured":"Migraine - Diagnosis. (2019). Accessed. August 11, 2022: https:\/\/www.nhs.uk\/conditions\/migraine\/diagnosis\/."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.li17059su1c","article-title":"Migraine headache: diagnosis and current and emerging preventive treatments","volume":"20","author":"Lipton RB","year":"2018","unstructured":"Lipton RB, Silberstein S. Migraine headache: diagnosis and current and emerging preventive treatments. Prim Care Companion CNS Disord. 2018, 20:PCC.li17059su1c. 10.4088\/PCC.li17059su1c","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111557","article-title":"Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine","volume":"139","author":"Khan J","year":"2021","unstructured":"Khan J, Asoom LI, Sunni AA, et al.. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021, 139:111557. 10.1016\/j.biopha.2021.111557","journal-title":"Biomed Pharmacother"},{"key":"ref27","article-title":"Migraine overview and summary of current and emerging treatment options","volume":"25","author":"Peters GL","year":"2019","unstructured":"Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019, 25:S23-34.","journal-title":"Am J Manag Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12409","article-title":"Clinical characteristics and management of headache: a real-life prospective, observational study from a tertiary care center in eastern India","volume":"12","author":"Nayak S","year":"2020","unstructured":"Nayak S, Parida M, Das SB, et al.. Clinical characteristics and management of headache: a real-life prospective, observational study from a tertiary care center in eastern India. Cureus. 2020, 12:e12409. 10.7759\/cureus.12409","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11080465","article-title":"Botulinum toxin a valuable prophylactic agent for migraines and a possible future option for the prevention of hormonal variations-triggered migraines","volume":"11","author":"Dima L","year":"2019","unstructured":"Dima L, B\u0103lan A, Moga MA, Dinu CG, Dimienescu OG, Varga I, Neculau AE. Botulinum toxin a valuable prophylactic agent for migraines and a possible future option for the prevention of hormonal variations-triggered migraines. Toxins. 2019, 11:465. 10.3390\/toxins11080465","journal-title":"Toxins"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12120803","article-title":"Botulinum toxin in the treatment of headache","volume":"12","author":"Becker WJ","year":"2020","unstructured":"Becker WJ. Botulinum toxin in the treatment of headache. Toxins. 2020, 12:803. 10.3390\/toxins12120803","journal-title":"Toxins"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam PK","year":"2010","unstructured":"Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010, 55:8-14. 10.4103\/0019-5154.60343","journal-title":"Indian J Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002676","article-title":"Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients","volume":"20","author":"Schim J","year":"2004","unstructured":"Schim J. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Curr Med Res Opin. 2004, 20:49-53. 10.1185\/030079903125002676","journal-title":"Curr Med Res Opin"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2003.12.031","article-title":"Botulinum neurotoxin for the treatment of migraine and other primary headache disorders","volume":"22","author":"Dodick D","year":"2004","unstructured":"Dodick D, Blumenfeld A, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Clin Dermatol. 2004, 22:76-81. 10.1016\/j.clindermatol.2003.12.031","journal-title":"Clin Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.5.463","article-title":"Botulinum toxin type A in chronic migraine","volume":"7","author":"Freitag FG","year":"2007","unstructured":"Freitag FG. Botulinum toxin type A in chronic migraine. Expert Rev Neurother. 2007, 7:463-70. 10.1586\/14737175.7.5.463","journal-title":"Expert Rev Neurother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05067.x","article-title":"Duration of migraine is a predictor for response to botulinum toxin type A","volume":"45","author":"Eross EJ","year":"2005","unstructured":"Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Duration of migraine is a predictor for response to botulinum toxin type A. Headache. 2005, 45:308-14. 10.1111\/j.1526-4610.2005.05067.x","journal-title":"Headache"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/164_2020_365","article-title":"The use of botulinum toxin in the management of headache disorders","volume":"263","author":"Yuan H","year":"2021","unstructured":"Yuan H, Silberstein SD. The use of botulinum toxin in the management of headache disorders. Handb Exp Pharmacol. 2021, 263:227-49. 10.1007\/164_2020_365","journal-title":"Handb Exp Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02742-x","article-title":"OnabotulinumtoxinA in chronic migraine: is the response dose dependent?","volume":"22","author":"Zandieh A","year":"2022","unstructured":"Zandieh A, Cutrer FM. OnabotulinumtoxinA in chronic migraine: is the response dose dependent?. BMC Neurol. 2022, 22:218. 10.1186\/s12883-022-02742-x","journal-title":"BMC Neurol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2008.14.5.442","article-title":"Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization","volume":"14","author":"Mitchell MP","year":"2008","unstructured":"Mitchell MP, Schaecher K, Cannon HE, Speckman M. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization. J Manag Care Pharm. 2008, 14:442-50. 10.18553\/jmcp.2008.14.5.442","journal-title":"J Manag Care Pharm"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-1103-y","article-title":"Botulinum toxin in migraine prophylaxis","volume":"251","author":"G\u00f6bel H","year":"2004","unstructured":"G\u00f6bel H. Botulinum toxin in migraine prophylaxis. J Neurol. 2004, 251:I8-11. 10.1007\/s00415-004-1103-y","journal-title":"J Neurol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132898","article-title":"OnabotulinumtoxinA in migraine: a review of the literature and factors associated with efficacy","volume":"10","author":"Ray JC","year":"2021","unstructured":"Ray JC, Hutton EJ, Matharu M. OnabotulinumtoxinA in migraine: a review of the literature and factors associated with efficacy. J Clin Med. 2021, 10:2898. 10.3390\/jcm10132898","journal-title":"J Clin Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00066.x","article-title":"Botulinum toxin type A as a migraine preventive treatment. For the BOTOX migraine clinical research group","volume":"40","author":"Silberstein S","year":"2000","unstructured":"Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX migraine clinical research group. Headache. 2000, 40:445-50. 10.1046\/j.1526-4610.2000.00066.x","journal-title":"Headache"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1707803","article-title":"Application of botulinum toxin in pregnancy and its impact on female reproductive health","volume":"19","author":"Li W","year":"2020","unstructured":"Li W, Tang M. Application of botulinum toxin in pregnancy and its impact on female reproductive health. Expert Opin Drug Saf. 2020, 19:83-91. 10.1080\/14740338.2020.1707803","journal-title":"Expert Opin Drug Saf"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-016-0545-0","article-title":"Botulinum toxin: pharmacology and therapeutic roles in pain states","volume":"20","author":"Patil S","year":"2016","unstructured":"Patil S, Willett O, Thompkins T, et al.. Botulinum toxin: pharmacology and therapeutic roles in pain states. Curr Pain Headache Rep. 2016, 20:15. 10.1007\/s11916-016-0545-0","journal-title":"Curr Pain Headache Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00624.x","article-title":"Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study","volume":"47","author":"Aurora SK","year":"2007","unstructured":"Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007, 47:486-99. 10.1111\/j.1526-4610.2006.00624.x","journal-title":"Headache"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-282x2005000100035","article-title":"Botulinum toxin: mechanisms of action","volume":"63","author":"Dressler D","year":"2005","unstructured":"Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005, 63:180-5. 10.1590\/s0004-282x2005000100035","journal-title":"Arq Neuropsiquiatr"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: a review in the prevention of chronic migraine","volume":"78","author":"Frampton JE","year":"2018","unstructured":"Frampton JE, Silberstein S. OnabotulinumtoxinA: a review in the prevention of chronic migraine. Drugs. 2018, 78:589-600. 10.1007\/s40265-018-0894-6","journal-title":"Drugs"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3284446","article-title":"Botox (OnabotulinumtoxinA) for treatment of migraine symptoms: a systematic review","volume":"2022","author":"Shaterian N","year":"2022","unstructured":"Shaterian N, Shaterian N, Ghanaatpisheh A, et al.. Botox (OnabotulinumtoxinA) for treatment of migraine symptoms: a systematic review. Pain Res Manag. 2022, 2022:1-15. 10.1155\/2022\/3284446","journal-title":"Pain Res Manag"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000136","article-title":"Role of botulinum toxin in depression","volume":"22","author":"Parsaik AK","year":"2016","unstructured":"Parsaik AK, Mascarenhas SS, Hashmi A, Prokop LJ, John V, Okusaga O, Singh B. Role of botulinum toxin in depression. J Psychiatr Pract. 2016, 22:99-110. 10.1097\/PRA.0000000000000136","journal-title":"J Psychiatr Pract"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14060383","article-title":"Treatment of depression with botulinum toxin","volume":"14","author":"Wollmer MA","year":"2022","unstructured":"Wollmer MA, Magid M, Kruger TH, Finzi E. Treatment of depression with botulinum toxin. Toxins. 2022, 14:383. 10.3390\/toxins14060383","journal-title":"Toxins"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1356093","article-title":"Botulinum toxin for the treatment of major depressive disorder. (Article in German)","volume":"82","author":"Hawlik AE","year":"2014","unstructured":"Hawlik AE, Freudenmann RW, Pinkhardt EH, Sch\u00f6nfeldt-Lecuona CJ, Gahr M. Botulinum toxin for the treatment of major depressive disorder. (Article in German). Fortschr Neurol Psychiatr. 2014, 82:93-9. 10.1055\/s-0033-1356093","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.719467","article-title":"Lifestyle modifications for migraine management","volume":"13","author":"Agbetou M","year":"2022","unstructured":"Agbetou M, Adoukonou T. Lifestyle modifications for migraine management. Front Neurol. 2022, 13:719467. 10.3389\/fneur.2022.719467","journal-title":"Front Neurol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03837-z","article-title":"Sleep disorder-related headaches","volume":"40","author":"Ferini-Strambi L","year":"2019","unstructured":"Ferini-Strambi L, Galbiati A, Combi R. Sleep disorder-related headaches. Neurol Sci. 2019, 40:107-13. 10.1007\/s10072-019-03837-z","journal-title":"Neurol Sci"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-020-00929-w","article-title":"Exercise in treatment of migraine including chronic migraine","volume":"25","author":"Song TJ","year":"2021","unstructured":"Song TJ, Chu MK. Exercise in treatment of migraine including chronic migraine. Curr Pain Headache Rep. 2021, 25:14. 10.1007\/s11916-020-00929-w","journal-title":"Curr Pain Headache Rep"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2015.07.005","article-title":"Cognitive behavior therapy for comorbid migraine and\/or tension-type headache and major depressive disorder: an exploratory randomized controlled trial","volume":"73","author":"Martin PR","year":"2015","unstructured":"Martin PR, Aiello R, Gilson K, Meadows G, Milgrom J, Reece J. Cognitive behavior therapy for comorbid migraine and\/or tension-type headache and major depressive disorder: an exploratory randomized controlled trial. Behav Res Ther. 2015, 73:8-18. 10.1016\/j.brat.2015.07.005","journal-title":"Behav Res Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/117032-the-development-of-psychiatric-illness-and-chemoprophylaxis-of-botulinum-toxin-in-migraine-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:38Z","timestamp":1707508118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/117032-the-development-of-psychiatric-illness-and-chemoprophylaxis-of-botulinum-toxin-in-migraine-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.32998","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}